BioCentury
ARTICLE | Clinical News

PLX3397: Phase II data

June 2, 2014 7:00 AM UTC

An open-label, U.S. Phase II trial in 38 patients with recurrent glioblastoma showed that once-daily 1,000 mg oral PLX3397 led to 6-month PFS rate of 11.4% with no complete or partial responses reported. There were 7 cases of stable disease. PLX3397 was well tolerated with fatigue, constipation, nausea, hair color change, elevations in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, anorexia, and headache reported as the most common treatment-related adverse events. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...